Most of the drug industry is racing to build GLP-1 agonists for weight loss and diabetes. Amylyx Pharmaceuticals bet on the opposite — a GLP-1 blocker — and the wager has paid off.

Avexitide, a GLP-1 receptor antagonist, hit its primary goal in a late-stage trial for post-bariatric hypoglycaemia, delivering a 55% reduction in serious-to-severe hypoglycaemic events versus placebo. Shares rose about 14% after hours.

The condition

Post-bariatric hypoglycaemia is a complication of weight-loss surgery that sounds paradoxical and is genuinely dangerous.

After surgery that reroutes the digestive tract, food reaches the small intestine faster than it should. That triggers an exaggerated release of gut hormones including GLP-1, which drives an oversized insulin response — and because the insulin surge outlasts the glucose it was responding to, blood sugar crashes an hour or two after eating.

Severe episodes cause confusion, loss of consciousness and seizures. Patients describe organising their lives around the risk: avoiding driving after meals, eating constantly in small amounts, and living with the knowledge that an episode can arrive without warning.

Why blocking GLP-1 is the logical treatment

The mechanism explains itself once the cause is understood. If the problem is excessive GLP-1 signalling driving too much insulin, blocking the GLP-1 receptor should blunt it.

That is precisely the inverse of what the obesity and diabetes field is doing, which makes it a striking asset to hold in 2026 — and entirely coherent. The same hormone that is therapeutic when boosted in one condition is pathological when excessive in another.

The result and the side effects

A 55% reduction in serious-to-severe events is the outcome that matters, because it counts the episodes patients fear rather than measuring average glucose.

Side effects were mostly mild to moderate, commonly diarrhoea and injection-site reactions — unremarkable for an injectable peptide, and notably not including the counter-problem one might worry about, since blocking GLP-1 could in principle worsen glucose control in the other direction.

Co-CEO Joshua Cohen called the results a “home run…far above most expectations”; co-CEO Justin Klee noted that “preventing even a single event matters.”

An underserved and growing condition

Post-bariatric hypoglycaemia has no FDA-approved treatment, even as bariatric surgery becomes more common.

Current management is dietary — small frequent low-carbohydrate meals — supplemented by off-label drugs with limited evidence. For patients whose episodes persist despite that, the options effectively run out.

The population is also expanding. Bariatric surgery volumes have grown substantially, and the complication typically appears one to several years afterwards, so incidence lags the procedures by years.

Avexitide already holds breakthrough therapy designation, and Amylyx plans to file for FDA approval before the end of 2026.

The turnaround story

The commercial history is remarkable. Amylyx acquired avexitide for just $35 million out of Eiger BioPharmaceuticals’ 2024 bankruptcy. Analysts now estimate peak sales of $1.3–$1.5 billion.

Buying assets from distressed sellers is a recognised strategy and rarely produces returns of this order. A bankrupt company sells everything, including programmes that are scientifically sound but that it lacked the capital to advance — and the discount reflects the seller’s situation rather than the asset’s quality.

The context matters for Amylyx specifically. The company had its own difficult period after its lead ALS drug was withdrawn following a failed confirmatory trial, and rebuilding around an acquired asset that has now read out positively is an unusually clean recovery.

The wider pattern

The programme illustrates how the GLP-1 boom is spawning adjacent opportunities — including managing the metabolic consequences of weight-loss interventions.

That category is likely to grow. Interventions producing rapid, substantial metabolic change generate their own complications, and the population experiencing them is expanding quickly. Post-bariatric hypoglycaemia is the surgical version of a problem that pharmacological weight loss may produce its own variants of.

What remains

Topline results are not a filing, and a filing is not an approval. The full data will need to show the effect holds across severity levels and that the reduction in events translates into patients regaining normal activity rather than merely recording fewer episodes.

What this suggests about GLP-1 drugs

The condition avexitide treats raises a question worth asking about the pharmacological weight-loss boom.

Post-bariatric hypoglycaemia arises from surgically altered anatomy producing excessive GLP-1 release. GLP-1 receptor agonists produce sustained receptor stimulation by a different route — and while they do not cause the same post-meal insulin surge, since they act on glucose-dependent insulin release, the long-term consequences of years of pharmacological GLP-1 signalling on the same axis are not fully characterised.

Reports of hypoglycaemia in people taking these drugs exist and are uncommon, generally in patients also taking insulin or sulfonylureas where the interaction is understood.

The honest position is that surgical and pharmacological GLP-1 elevation are mechanistically different enough that one should not be read directly onto the other. But a drug company holding a GLP-1 antagonist as tens of millions of people take GLP-1 agonists is in an interesting position, and the adjacency is unlikely to have escaped anyone’s notice.

For a condition with no approved therapy and a defined mechanism the drug directly addresses, the path is unusually clear. Clinical and business news, not medical or investment advice.